Literature DB >> 29387880

Outpatient Worsening Heart Failure as a Target for Therapy: A Review.

Stephen J Greene1,2, Robert J Mentz1,2, G Michael Felker1,2.   

Abstract

Importance: Hospitalizations for worsening heart failure (WHF) represent an enormous public health and financial burden, with physicians, health systems, and payers placing increasing emphasis on hospitalization prevention. In addition, maximizing time out of the hospital is an important patient-centered outcome. In this review, we discuss the concept of outpatient WHF, highlight the rationale and data for the outpatient treatment of WHF as an alternative to hospitalization, and examine opportunities and strategies for developing outpatient "interceptive" therapies for treatment of worsening symptoms and prevention of hospitalization. Observations: Worsening heart failure has traditionally been synonymous with an episode of in-hospital care for worsening symptoms. While WHF often leads to hospitalization, many patients experience WHF in the outpatient setting and carry a similarly poor prognosis. These findings support WHF as a distinct condition, independent of location of care. For those that are hospitalized, most patients have an uncomplicated clinical course, with diuretics as the only intravenous therapy. Although complicated scenarios exist, it is conceivable that improved tools for outpatient management of clinical congestion would allow a greater proportion of hospitalized patients to receive comparable care outside the hospital. Most patients with WHF have a gradual onset of congestive signs and symptoms, offering a potential window in which effective therapy may abort continued worsening and obviate the need for hospitalization. To date, outpatient WHF has received minimal attention in randomized clinical trials, but this high-risk group possesses key features that favor effective clinical trial investigation. Conclusions and Relevance: As the public health and economic burdens of heart failure continue to grow, recognizing the entity of outpatient WHF is critical. Efforts to reduce heart failure hospitalization should include developing effective therapies and care strategies for outpatient WHF. The outpatient WHF population represents a major opportunity for therapeutic advancements that could fundamentally change heart failure care delivery.

Entities:  

Mesh:

Year:  2018        PMID: 29387880      PMCID: PMC7474527          DOI: 10.1001/jamacardio.2017.5250

Source DB:  PubMed          Journal:  JAMA Cardiol            Impact factor:   14.676


  67 in total

1.  Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.

Authors:  Michael S Cuffe; Robert M Califf; Kirkwood F Adams; Raymond Benza; Robert Bourge; Wilson S Colucci; Barry M Massie; Christopher M O'Connor; Ileana Pina; Rebecca Quigg; Marc A Silver; Mihai Gheorghiade
Journal:  JAMA       Date:  2002-03-27       Impact factor: 56.272

Review 2.  Acute Heart Failure: Alternatives to Hospitalization.

Authors:  Reka Zsilinszka; Robert J Mentz; Adam D DeVore; Zubin J Eapen; Peter S Pang; Adrian F Hernandez
Journal:  JACC Heart Fail       Date:  2017-03-08       Impact factor: 12.035

3.  Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database.

Authors:  Clyde W Yancy; Margarita Lopatin; Lynne Warner Stevenson; Teresa De Marco; Gregg C Fonarow
Journal:  J Am Coll Cardiol       Date:  2005-12-15       Impact factor: 24.094

4.  Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from PARTNERS HF (Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure) study.

Authors:  David J Whellan; Kevin T Ousdigian; Sana M Al-Khatib; Wenji Pu; Shantanu Sarkar; Charles B Porter; Behzad B Pavri; Christopher M O'Connor
Journal:  J Am Coll Cardiol       Date:  2010-04-27       Impact factor: 24.094

5.  Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF).

Authors:  Gregg C Fonarow; Nancy M Albert; Anne B Curtis; Wendy Gattis Stough; Mihai Gheorghiade; J Thomas Heywood; Mark L McBride; Patches Johnson Inge; Mandeep R Mehra; Christopher M O'Connor; Dwight Reynolds; Mary Norine Walsh; Clyde W Yancy
Journal:  Circulation       Date:  2010-07-26       Impact factor: 29.690

6.  Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study.

Authors:  G Michael Felker; Robert J Mentz; John R Teerlink; Adriaan A Voors; Peter S Pang; Piotr Ponikowski; Barry H Greenberg; Gerasimos Filippatos; Beth A Davison; Gad Cotter; Margaret F Prescott; Tsushung A Hua; Sara Lopez-Pintado; Thomas Severin; Marco Metra
Journal:  Eur J Heart Fail       Date:  2015-09-03       Impact factor: 15.534

7.  The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries.

Authors:  Andrew P Ambrosy; Gregg C Fonarow; Javed Butler; Ovidiu Chioncel; Stephen J Greene; Muthiah Vaduganathan; Savina Nodari; Carolyn S P Lam; Naoki Sato; Ami N Shah; Mihai Gheorghiade
Journal:  J Am Coll Cardiol       Date:  2014-02-05       Impact factor: 24.094

8.  Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure.

Authors:  Milton Packer; Wilson Colucci; Lloyd Fisher; Barry M Massie; John R Teerlink; James Young; Robert J Padley; Roopal Thakkar; Leticia Delgado-Herrera; Jeffrey Salon; Chris Garratt; Bidan Huang; Toni Sarapohja
Journal:  JACC Heart Fail       Date:  2013-04-01       Impact factor: 12.035

9.  Diuretic effects of subcutaneous furosemide in human volunteers: a randomized pilot study.

Authors:  Arun K Verma; Jack H da Silva; David R Kuhl
Journal:  Ann Pharmacother       Date:  2004-02-24       Impact factor: 3.154

10.  Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.

Authors:  Burkert Pieske; Aldo P Maggioni; Carolyn S P Lam; Elisabeth Pieske-Kraigher; Gerasimos Filippatos; Javed Butler; Piotr Ponikowski; Sanjiv J Shah; Scott D Solomon; Andrea-Viviana Scalise; Katharina Mueller; Lothar Roessig; Mihai Gheorghiade
Journal:  Eur Heart J       Date:  2017-04-14       Impact factor: 29.983

View more
  23 in total

1.  Outpatient versus inpatient worsening heart failure: distinguishing biology and risk from location of care.

Authors:  Stephen J Greene; G Michael Felker; Javed Butler
Journal:  Eur J Heart Fail       Date:  2018-11-05       Impact factor: 15.534

Review 2.  Nomenclature in heart failure: a call for objective, reproducible, and biologically-driven terminology.

Authors:  Ravi B Patel; Muthiah Vaduganathan; Stephen J Greene; Javed Butler
Journal:  Eur J Heart Fail       Date:  2018-06-26       Impact factor: 15.534

Review 3.  Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues.

Authors:  Javed Butler; Milton Packer; Stephen J Greene; Mona Fiuzat; Stefan D Anker; Kevin J Anstrom; Peter E Carson; Lauren B Cooper; Gregg C Fonarow; Adrian F Hernandez; James L Januzzi; Mariell Jessup; Rita R Kalyani; Sanjay Kaul; Mikhail Kosiborod; JoAnn Lindenfeld; Darren K McGuire; Marc S Sabatine; Scott D Solomon; John R Teerlink; Muthiah Vaduganathan; Clyde W Yancy; Norman Stockbridge; Christopher M O'Connor
Journal:  Circulation       Date:  2019-12-16       Impact factor: 29.690

4.  Outpatient Intravenous Diuretic Therapy for Heart Failure in the United States.

Authors:  Stephen J Greene; Lauren E Wilson; Siddique A Abbasi; Akeem A Yusuf; Bradley G Hammill
Journal:  J Am Coll Cardiol       Date:  2019-03-12       Impact factor: 24.094

5.  Relationship between timing of trial randomization, protocol completion, and clinical outcomes among patients hospitalized for heart failure: from the ASTRONAUT trial.

Authors:  Stephen J Greene; Gregg C Fonarow; Scott D Solomon; Haris P Subacius; Muthiah Vaduganathan; Andrew P Ambrosy; Marat Fudim; Michael Böhm; Aldo P Maggioni; Eldrin F Lewis; Faiez Zannad; Javed Butler
Journal:  Eur J Heart Fail       Date:  2018-11-11       Impact factor: 15.534

Review 6.  Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes.

Authors:  Stephen J Greene; Muthiah Vaduganathan; Muhammad Shahzeb Khan; George L Bakris; Matthew R Weir; Jonathan H Seltzer; Naveed Sattar; Darren K McGuire; James L Januzzi; Norman Stockbridge; Javed Butler
Journal:  J Am Coll Cardiol       Date:  2018-03-10       Impact factor: 24.094

Review 7.  Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes.

Authors:  Eberhard Standl; Oliver Schnell; Darren K McGuire
Journal:  Circ Res       Date:  2016-05-27       Impact factor: 17.367

Review 8.  Evolving therapeutic strategies for patients hospitalized with new or worsening heart failure across the spectrum of left ventricular ejection fraction.

Authors:  John W Ostrominski; Muthiah Vaduganathan
Journal:  Clin Cardiol       Date:  2022-06       Impact factor: 3.287

Review 9.  Factors associated with non-use and sub-target dosing of medical therapy for heart failure with reduced ejection fraction.

Authors:  Stephen J Greene; Xi Tan; Yu-Chen Yeh; Mark Bernauer; Omer Zaidi; Mei Yang; Javed Butler
Journal:  Heart Fail Rev       Date:  2021-01-20       Impact factor: 4.214

10.  Comprehensive Outpatient Management of Low-Risk Pulmonary Embolism: Can Primary Care Do This? A Narrative Review.

Authors:  David R Vinson; Drahomir Aujesky; Geert-Jan Geersing; Pierre-Marie Roy
Journal:  Perm J       Date:  2020-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.